RxDoctor Payments Data

Robert Higginbotham, MD

Ophthalmology · San Luis Obispo, CANPI 1609878834

Payments from drug & device makers

$2,720in general payments, 2019–2025

Across 52 payments — averaging $52.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Sight Sciences, Inc.$283
  • Bausch & Lomb Americas Inc.$233
  • Glaukos Corporation$157
  • Ivantis, Inc$148
  • Sun Pharmaceutical Industries Inc.$134
  • plus $620 from 11 others

What the payments were for

  • Food & beverage$2,720100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,720 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$450,171
Medicare patients
1,306
Services billed
3,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine46$42,806
Cyclosporine33$11,043
XiidraLifitegrast11$9,842
Tobramycin-DexamethasoneTobramycin/Dexamethasone162$8,408
IlevroNepafenac11$8,226
Dorzolamide-TimololDorzolamide/Timolol/Pf31$8,018
Latanoprost464$6,920
Prednisolone Acetate104$5,873
Bromfenac Sodium44$5,654
Travoprost20$3,825
CombiganBrimonidine Tartrate/Timolol15$3,709
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat124$2,990
ZioptanTafluprost/Pf13$2,970
Timolol Maleate48$2,033
Ofloxacin89$1,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$25$46,51561 claims
Bausch & Lomb Americas Inc.Xiidra$233$9,84211 claims
NovartisIlevro$43$8,22611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Luis Obispo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →